Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery

AIDS

Volumn 20, Issue 13, 2006, Pages 1737-1743

  Gingelmaier, Andrea ^a   Kurowski, Michael ^b   Kästner, Ralph ^a   Eberle, Josef ^a   Mylonas, Ioannis ^a   Belohradsky, Bernd H ^a   Friese, Klaus ^a   Grubert, Thomas A ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b Vivantes Auguste Viktoria Klinikum   (Germany)

^c Ludwig Maximilians University ^*

Author keywords

HIV 1; Nevirapine; Pharmacokinetics; Placental transfer; Pregnancy; Protease inhibitors

Indexed keywords

LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

AMNION FLUID; ARTICLE; CESAREAN SECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PLACENTAL TRANSFER; PREGNANT WOMAN; PRIORITY JOURNAL; STEADY STATE; TREATMENT OUTCOME; UMBILICAL CORD BLOOD;

AMNIOTIC FLUID; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE TRANSMISSION, VERTICAL; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; FETAL BLOOD; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NEVIRAPINE; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; PYRIMIDINONES; VIRAL LOAD;

EID: 33748068073     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000242820.67001.2c     Document Type: Article

References (32)

1. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863-1870.
2. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Def Syndr 2002; 29:484-494.
3. Public Health Service Task Force. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. Washington DC: US Public Health Service; 2005. Nov 17.
4. Krauer B, Krauer F, Hytten FE. Drug disposition and pharmacokinetics in the maternal-placental fetal unit. Pharmacol Ther 1980; 10:301-328.
5. Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol 2001; 15:819-826.
6. Mirochnick M, Siminski S, Fenton T, Lugo M, Sullivan JL. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001; 20:803-805.
7. Aweeka F, Lizak P, Frenkel L, Au S, Watts H, McNamara J, et al. Steady state nevirapine pharmacokinetics during second and third trimester pregnancy and postpartum: PACTG 1022 [Abstract]. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 923].
8. Haberl A, Hentig N, Carlebach A, Kurowski M, Harder S, Staszewski S. Nevirapine plasma exposure is decreased in pregnant women. XV International AIDS Conference, Bangkok, July 2004 [abstract TuPeB4644].
9. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003; 17:1195-1199.
10. Nellen JF, Schillevoort I, Wit FW, Bergshoeff AS, Godfried MH, Boer K, et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis 2004; 39:736-740.
11. Acosta EP, Zorrilla C, Van Dyke R, Bardeguez A, Smith E, Hughes M, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2001; 2:460-465.
12. Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48:430-436.
13. Stek A, Mirochnick M, Capparelli E, Best B, Burchett K, Hu C, et al. Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. XV International AIDS Conference, Bangkok, July 2004 [abstract LbOrB08].
14. Casey BM, Bawdon RE. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol 1998; 179:758-761.
15. Bawdon RE. Ex vivo human placental transfer of anti-human immunodeficiency virus compounds. J Inf Dis Obstet Gynecol 1998; 5:310-315.
16. Bawdon RE. The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir. J Inf Dis Obstet Gynecol 1999; 6:244-246.
17. Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13:479-486.
18. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178:368-374.
19. Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002; 21:835-838.
20. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002; 16:889-893.
21. Chappuy H, Tréluyer JM, Rey E, Dimet J, Fouché M, Firtion G, et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gyn 2004; 191:558-562.
22. Buchholz B, Grubert T, Marcus U, Beichert M, Gingelmaier A, Brockmeyer NH. German-Austrian recommendations for HIV-therapy in pregnancy: update May 2003. Eur J Med Res 2004; 9:287-303.
23. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite m8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25:393-399.
24. Kurowski M, Müller M, Arasteh K, Moecklinghoff C. Simultaneous monitoring of five protease inhibitors in HIV-infected patients by LC-tandem mass spectrometry. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [abstract 320].
25. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171:537-545.
26. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile an potential for clinical use. Exp Opin Invest Drugs 1996; 5:1183-1199.
27. Dusek A, Hall D, Lamson M. Once-daily dosing of nevirapine: a retrospective cross-study analysis. In: Extended version of the Abstracts from the 12th World AIDS Conference, Geneva June-July 1998. Bologna, Litosei: Monduzzi Editore S.p.A.; 1998:295-298.
28. de Vries-Sluijs TE, Dielemann JP, Arts D, Huitema AD, Beijnen JH, Schutten M, et al. Low nevirapine plasma concentration predict virological failure in an unselected HIV-1-infected population. Clin Pharmcokinet 2003; 42:599-605.
29. Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs 2000; 59:581-620.
30. Acosta EP. Pharamcokinetic enhancement of protease inhibitors. J Acquir Immune Defic Syndr 2002; 29 (Suppl 1):S11-S18.
31. Maiques V, Garcia-Tejedor A, Perales A, Cordoba J, Esteban RJ. HIV detection in amniotic fluid samples. Amniocentesis can be performed in HIV pregnant women? Eur J Obstet Gynecol Reprod Biol 2003; 108:137-141.
32. De Pasquale MP, Leigh Brown AJ, Uvin SC, Allega-Ingersoll J, Caliendo AM, Sutton L, et al. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34:37-44.